Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. [electronic resource]
Producer: 20030116Description: 1219-29 p. digitalISSN:- 0884-0431
- Animals
- Bone Density -- drug effects
- Bone Resorption -- metabolism
- Carrier Proteins -- genetics
- Cell Line
- Down-Regulation
- Gene Expression
- Glycoproteins -- genetics
- Male
- Melatonin -- administration & dosage
- Membrane Glycoproteins -- genetics
- Mice
- Osteoclasts -- cytology
- Osteoprotegerin
- RANK Ligand
- Receptor Activator of Nuclear Factor-kappa B
- Receptors, Cytoplasmic and Nuclear -- genetics
- Receptors, Tumor Necrosis Factor
- Tibia -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.